
Dedicated Drained Liver Volume Measurement after Percutaneous Biliary Drain Placement: A Personalized Three- Dimensional Volumetry Model

Ryan P. Kempen

Mentor: Alda Tam, MD, MBA

Department of Interventional Radiology

THE UNIVERSITY OF TEXAS
MDAnderson
Cancer Center

Making Cancer History®



Introduction

Malignant Bile Duct Obstruction (MBDO)


- Hyperbilirubinemia and improper bile excretion can affect administration of systemic chemotherapies^{1,2}
- Intervention: Percutaneous Transhepatic Biliary Drainage (PTBD)

Physicians cannot accurately assess the probability of success for PTBD to reduce total serum bilirubin level below a threshold that allows for continuation of systemic chemotherapy.


Proof-of-Concept Approach

- Train nnU-Net machine learning model to auto-segment CT scans into liver, biliary, and tumor segments³
- Validate biliary drainage volume in a sample of patients established to have increased likelihood of success: low obstruction with drained liver volume of 100%¹

Low Obstruction




High Obstruction



Methods


nnU-Net Training

1




EMR patient search: PTBD
January 2016 – May 2024

2



Manual Segmentation to
establish Ground Truth


3



nnU-Net algorithm trained to
auto-segment CT scans into
liver, tumors, and biliary tracts


Biliary Drainage Volume Verification

1




Ground Truth and nnU-Net 3D
models input to 3D Slicer:
SlicerLiver

2



SlicerLiver: Add centerlines to
identify biliary tract

3



SlicerLiver: Calculate Biliary
Drainage Territory Volume via
shortest distance mapping to
centerline(s)


nnU-Net Training

nnU-Net Training

- Training Cases: 44
- Validation Cases: 11

Dice Scores


- Liver: 0.9154
- Biliary: 0.6338
- Tumor: 0.6051





Low Obstruction Case Validation

Variable	Value
Total Patients	7
Age	
Median	62
Range	54 - 70
Gender	
Male	3
Female	4
Pre-ERCP ECOG	
Not documented	2
0	1
1	3
2	1
Cancer Type	
Pancreatic	6
Cholangiocarcinoma	1
Post-ERCP Total Bilirubin <1.2 mg/dL	
Yes	7
No	0
Days to Post-ERCP Total Bilirubin <1.2 mg/dL	
Median	69
Range	29 - 109

- Low obstruction with drained liver volume of 100%
- ERCP resulted in total serum biliary normalization for all patients






Low Obstruction Case Validation



Conclusions

- nnU-Net machine learning algorithm trained to auto-segment liver, biliary, and tumor segments from abdominal CT scans. Further training for biliary and tumor segments is needed to improve accuracy.
- Utilized nnU-Net auto-segmented 3D models to verify 100% drained liver volume in small sample of patients with low level MBDO.
- Future: use unified computational tool to measure dependent liver volume from pre- and post-PTBD CT scans to correlate drained liver volume to total serum bilirubin levels post-PTBD.



Acknowledgements

Mentors and Contributors

Alda Tam, MD, MBA

Ethan Lin, MD

David Fuentes, PhD

Brayden Mi

Koustav Pal, MBBS

Iwan Paolucci, PhD

SOAR

Jillian Gunther MD, PhD

Marites Melancon, PhD

Marvin Bernardino

Allan Barcena, PhD

Dominic Bolinas

Funding: RPK was supported by the Medical Students Summer in Oncology at Anderson Research (SOAR) Program, funded by NCI (R25 CA-265800-01A1)

References

1. Thornton RH, Ulrich R, Hsu M, Moskowitz C, Reidy-Lagunes D, Covey AM, Brody LA, Robson PM, Sofocleous CT, Solomon SB, Getrajdman GI, Brown KT. 2012. Outcomes of Patients Undergoing Percutaneous Biliary Drainage to Reduce Bilirubin for Administration of Chemotherapy. *J Vasc Interv Radiol*. 23(1):89-95. <https://doi.org/10.1016/j.jvir.2011.09.022>
2. Thornton RH, Covey AM. Management of Malignant Biliary Tract Obstruction. In: Image-Guided Interventions: Expert Radiology Series. 3rd ed. Philadelphia (PA): Elsevier; c2021. p.749-760.
3. Isensee F, Jaeger PF, Kohl SAA, Petersen J, Maier-Hein KH. 2021. nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation. *Nat Methods*. 18(2):203-211. <https://doi.org/10.1038/s41592-020-01008-z>

THE UNIVERSITY OF TEXAS
MD Anderson
~~Cancer~~ Center

Making Cancer History®

